Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
EyePoint Pharmaceuticals is a biotechnology business based in the US. EyePoint Pharmaceuticals stocks (EYPT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.01 – an increase of 6.16% over the previous week. EyePoint Pharmaceuticals employs 98 staff and has a trailing 12-month revenue of around $39.2 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Since the stock market crash in March caused by coronavirus, EyePoint Pharmaceuticals's stock price has had significant positive movement.
Its last market close was $11.72, which is 87.63% up on its pre-crash value of $1.45 and 1,346.91% up on the lowest point reached during the March crash when the stocks fell as low as $0.81.
If you had bought $1,000 worth of EyePoint Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $480.16 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $6,136.12.
|Latest market close||$11.72|
|52-week range||$3.511 - $15.06|
|50-day moving average||$10.3685|
|200-day moving average||$9.6579|
|Wall St. target price||$21.2|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.057|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-09-20)||10.46%|
|1 month (2021-08-27)||16.50%|
|3 months (2021-06-25)||23.11%|
|6 months (2021-03-26)||17.43%|
|1 year (2020-09-25)||1,979.12%|
|2 years (2019-09-27)||551.11%|
|3 years (2018-09-27)||211.70%|
|5 years (2016-09-27)||262.85%|
|Revenue TTM||USD$39.2 million|
|Gross profit TTM||USD$11.2 million|
|Return on assets TTM||-18.12%|
|Return on equity TTM||-74.85%|
|Market capitalisation||USD$337.2 million|
TTM: trailing 12 months
There are currently 1.4 million EyePoint Pharmaceuticals stocks held short by investors – that's known as EyePoint Pharmaceuticals's "short interest". This figure is 2.7% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting EyePoint Pharmaceuticals stocks can be evaluated.
EyePoint Pharmaceuticals's "short interest ratio" (SIR) is the quantity of EyePoint Pharmaceuticals stocks currently shorted divided by the average quantity of EyePoint Pharmaceuticals stocks traded daily (recently around 131709.54587581). EyePoint Pharmaceuticals's SIR currently stands at 10.79. In other words for every 100,000 EyePoint Pharmaceuticals stocks traded daily on the market, roughly 10790 stocks are currently held short.
However EyePoint Pharmaceuticals's short interest can also be evaluated against the total number of EyePoint Pharmaceuticals stocks, or, against the total number of tradable EyePoint Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EyePoint Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding stocks (for every 100,000 EyePoint Pharmaceuticals stocks in existence, roughly 50 stocks are currently held short) or 0.0833% of the tradable stocks (for every 100,000 tradable EyePoint Pharmaceuticals stocks, roughly 83 stocks are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the stock price and a discouraging interest in betting against EyePoint Pharmaceuticals.
Find out more about how you can short EyePoint Pharmaceuticals stock.
We're not expecting EyePoint Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
EyePoint Pharmaceuticals stocks were split on a 1:10 basis on 9 December 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyePoint Pharmaceuticals stocks – just the quantity. However, indirectly, the new 900% higher stock price could have impacted the market appetite for EyePoint Pharmaceuticals stocks which in turn could have impacted EyePoint Pharmaceuticals's stock price.
Over the last 12 months, EyePoint Pharmaceuticals's stocks have ranged in value from as little as $3.511 up to $15.06. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyePoint Pharmaceuticals's is 1.2942. This would suggest that EyePoint Pharmaceuticals's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Everything we know about the Peoples United Financial IPO, plus information on how to buy in. Read more…
We look at 6 popular stock discussion groups from Canada and overseas.Read more…
We’ve rounded up the top dividend stocks in Canada. Check out current stock prices, historical stock performance, company info and more.Read more…
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.